Targeting SARS-CoV-2 infection through CAR-T-like bispecific T cell engagers incorporating ACE2.

Mikail Dogan Lina KozhayaLindsey PlacekFatih KarabacakMesut YigitDerya Unutmaz

Published in: Clinical & translational immunology (2022)

In conclusion, these results suggest the potential of this approach as a variant-proof, therapeutic strategy for future SARS-CoV-2 variants, employing both humoral and cellular arms of the adaptive immune response.

Keyphrases

immune response
sars cov
respiratory syndrome coronavirus
current status
copy number
dendritic cells
angiotensin converting enzyme
cancer therapy
angiotensin ii
toll like receptor
human health
gene expression
risk assessment
dna methylation
climate change